Alembic Pharmaceuticals receives USFDA Tentative Approval for Rivaroxaban Tablets, 10 mg, 15 mg, and 20 mg.

Alembic Pharmaceuticals receives USFDA Tentative Approval for Rivaroxaban Tablets, 10 mg, 15 mg, and 20 mg.     Alembic Pharmaceuticals Limited today announced that the Company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Rivaroxaban Tablets, 10 mg, 15 mg, and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Xarelto Tablets, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals, Inc. (Janssen). Alembic Pharmaceuticals announces USFDA Final Approval for Doxycycline Hyclate…

Read More

L&T Hydrocarbon Engineering signs MoU with KBR for Refinery and Petrochemical Projects

L&T Hydrocarbon Engineering signs MoU with KBR for Refinery and Petrochemical Projects     L&T Hydrocarbon Engineering (LTHE), a wholly-owned subsidiary of Larsen 0 Toubro (L&T), has signed a memorandum of understanding with KBR to build Modular Process Plants for refinery and petrochemical projects Under the terms of the agreement, KBR and LTHE will collaborate to develop business opportunities and LTHE will exclusively bid for KBR’s solid acid alkylation technology (K-SAATTm), solvent de-asphalting technology (ROSE®) and catalytic olefins technology (K-COTTm) for global projects with special emphasis on India, South East…

Read More